Minerva Neurosciences (NERV) Earns News Sentiment Rating of 0.17
Media headlines about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Minerva Neurosciences earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.5896615782192 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several analysts have recently commented on NERV shares. BidaskClub upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. Citigroup lifted their target price on shares of Minerva Neurosciences to $19.00 in a research report on Friday, August 3rd. ValuEngine upgraded shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a report on Thursday, May 3rd. Finally, Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 15th.
NERV traded down $0.10 during trading on Friday, hitting $10.40. The company had a trading volume of 6,989 shares, compared to its average volume of 255,231. The stock has a market capitalization of $393.56 million, a PE ratio of -9.68 and a beta of 1.49. Minerva Neurosciences has a 1-year low of $4.80 and a 1-year high of $10.65.
In other Minerva Neurosciences news, COO Joseph H. Reilly sold 25,000 shares of the company’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the sale, the chief operating officer now directly owns 39,177 shares of the company’s stock, valued at approximately $391,770. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.60% of the stock is currently owned by corporate insiders.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.